newsfilter
← Latest News
PR Newswire·

Medivir receives regulatory approval from MHRA for phase 1/2a combination study with MIV-818

STOCKHOLM, Aug. 31, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the company has received regulatory approval from the British Medicines & Healthcare products Regulatory Agency (MHRA) for its upcoming phase 1/2a combinat